Managing the risks of mood symptoms with LNG-IUS: a clinical perspective

References

• Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci. 2008;33:331–343.
   PubMed Web of Science ®Google Scholar
• Toffoletto S, Lanzenberger R, Gingnell M, et al. Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: a systematic review. Psychoneuroendocrinology. 2014;50:28–52.
   PubMed Web of Science ®Google Scholar
• Soares CN. Mood disorders in midlife women: understanding the critical window and its clinical implications. Menopause. 2014;21:198–206.
   PubMed Web of Science ®Google Scholar
• Keita GP. Psychosocial and cultural contributions to depression in women: considerations for women midlife and beyond. J Manag Care Pharm. 2007;13:12–S15.
   PubMed Web of Science ®Google Scholar
• Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63:385–390.
   PubMed Web of Science ®Google Scholar
• Bitzer J. Hormonal contraception and depression: another Pill scandal? Eur J Contracept Reprod Health Care. 2017;22:1–2.
   PubMed Web of Science ®Google Scholar
• Lokuge S, Frey BN, Foster JA, et al. Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin. J Clin Psychiatry. 2011;72:e1563–e1569.
   PubMedGoogle Scholar
• Aleknaviciute J, Tulen JHM, De Rijke YB, et al. The levonorgestrel-releasing intrauterine device potentiates stress reactivity. Psychoneuroendocrinology. 2017;80:39–45.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Apter D, Bartfai G. ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives. Eur J Contracept Reprod Health Care. 2017;22:247–249.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 23–26 October [Cited 2018 Feb 28] 2017. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2018/01/WC500240971.pdf.
   Google Scholar
• Lundin C, Danielsson KG, Bixo M. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle – A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2017;76:135–143.
   PubMed Web of Science ®Google Scholar
• Schaffir J, Worly BL, Gur TL. Combined hormonal contraception and its effects on mood: a critical review. Eur J Contracept Reprod Health Care. 2016;21:347–345.
   PubMed Web of Science ®Google Scholar
• Kelly S, Davies E, Fearns S, et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study. Clin Drug Investig. 2010;30:325–336.
   PubMed Web of Science ®Google Scholar
• Ernst U, Baumgartner L, Bauer U, et al. Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: results of an observational clinical evaluation. Eur J Contracept Reprod Health Care. 2002;7:238–243.
   PubMed Web of Science ®Google Scholar
• Oddens BJ. Women’s satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception. 1999;59:277–286.
   PubMed Web of Science ®Google Scholar
• Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord. 2002;70:229–240.
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Morgan M, Sogliano C, et al. Decreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changes. Fertil Steril. 2006;85:1371–1378.
   PubMed Web of Science ®Google Scholar
• Skovlund CW, Kessing LV, Mørch LS, et al. Increase in depression diagnoses and prescribed antidepressants among young girls. A national cohort study 2000–2013. Nord J Psychiatry. 2017;71:378–385.
   PubMed Web of Science ®Google Scholar
• Skovlund CW, Mørch LS, Kessing LV, et al. Association of hormonal contraception with depression. JAMA Psychiatry. 2016;73:1154–1162.
   PubMed Web of Science ®Google Scholar
• Bengtsdotter H, Lundin C, Gemzell Danielsson K, et al. Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use. Eur J Contracept Reprod Health Care. 2018;23:45–51.
   PubMed Web of Science ®Google Scholar
• Bayer AG, Mirena® (levonorgestrel-releasing intrauterine system) Prescribing Information, [Internet]; 2018 [cited 2018 Feb 28]. Available from: https://www.medicines.org.uk/emc/product/1132
   Google Scholar
• Bayer AG, Jaydess® (levonorgestrel-releasing intrauterine system) Prescribing Information, [Internet]; 2017 [cited 2018 Feb 28]. Available from: https://www.medicines.org.uk/emc/product/5297
   Google Scholar
• Bayer AG, Kyleena® (levonorgestrel-releasing intrauterine system) Prescribing Information, [Internet]; 2017 [cited 2018 Feb 28]. Available from: https://www.medicines.org.uk/emc/product/769
   Google Scholar
• Gedeon Richter (UK) Ltd. Levosert® Prescribing Information, [Internet]; 2018 [cited 2018 Feb 28]. Available from: https://www.medicines.org.uk/emc/product/1789
   Google Scholar
• Apter D, Gemzell-Danielsson K, Hauck B, et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014;101:1656–1662.
   PubMed Web of Science ®Google Scholar
• Hall JA, Mann S, Lewis G, et al. Conceptual framework for integrating ‘Pregnancy Planning and Prevention’ (P3). J Fam Plann Reprod Health Care. 2015;42:75–76.
   PubMedGoogle Scholar
• Grunloh DS, Casner T, Secura GM, et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013;122:1214–1221.
   PubMed Web of Science ®Google Scholar
• Rose SB, Lawton BA, Brown SA. Uptake and adherence to long-acting reversible contraception post-abortion. Contraception. 2010;82:345–353.
   PubMed Web of Science ®Google Scholar
• Tewari R, Kay VJ. Compliance and user satisfaction with the intra-uterine contraceptive device in Family Planning Service: the results of a survey in Fife, Scotland, August 2004. Eur J Contracept Reprod Health Care. 2006;11:28–37.
   PubMed Web of Science ®Google Scholar
• Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49:56–72.
   PubMed Web of Science ®Google Scholar
• Sivin I, el Mahgoub S, McCarthy T, et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990;42:361–378.
   PubMed Web of Science ®Google Scholar
• Toffol E, Heikinheimo O, Koponen P, et al. Further evidence for lack of negative associations between hormonal contraception and mental health. Contraception. 2012;86:470–480.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. Eur J Obstet Gynecol Reprod Biol. 2017;210:22–28.
   PubMed Web of Science ®Google Scholar
• Roberts TA, Hansen S. Association of hormonal contraception with depression in the postpartum period. Contraception. 2017;96:446–452.
   PubMed Web of Science ®Google Scholar
• Pagano HP, Zapata LB, Berry-Bibee EN, et al. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. Contraception. 2016;94:641–649.
   PubMed Web of Science ®Google Scholar
• Tazegül Pekin A, Seçilmiş Kerimoğlu O, Kebapcılar AG, et al. Depressive symptomatology and quality of life assessment among women using the levonorgestrel-releasing intrauterine system: an observational study. Arch Gynecol Obstet. 2014;290:507–511.
   PubMed Web of Science ®Google Scholar
• Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry. 2017;4:146–158.
   PubMed Web of Science ®Google Scholar
• Gulland A. Women have higher rates of mental disorders than men, NHS survey finds. Bmj. 2016;354:i5320
   PubMedGoogle Scholar
• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29:85–96.
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol. 2003;189:1523–1530.
   PubMed Web of Science ®Google Scholar
• Kailasam C, Cahill D. Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system. Patient Prefer Adherence. 2008;2: 293–301.
   PubMedGoogle Scholar
• Alvarez F, Faundes A, Johansson E, et al. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills. Fertil Steril. 1983;40:120–123.
   PubMed Web of Science ®Google Scholar